• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃肠道间质瘤复发转移的危险因素及预后分析。

Risk Factors and Prognostic Analysis of Gastrointestinal Stromal Tumor Recurrence-Metastasis.

机构信息

First Clinical College of Wenzhou Medical University, Wenzhou, China.

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

出版信息

Comput Math Methods Med. 2022 Jul 18;2022:1127146. doi: 10.1155/2022/1127146. eCollection 2022.

DOI:10.1155/2022/1127146
PMID:35898476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9313930/
Abstract

OBJECTIVE

Gastrointestinal stromal tumors (GISTs) are potential malignancies that occur in the digestive tract. This study aimed to investigate the risk factors and prognosis of recurrence and metastasis of gastrointestinal stromal tumor (GIST).

METHODS

From January 2018 to December 2019, 422 patients with GIST who received surgery in the First Affiliated Hospital of Wenzhou Medical University were enrolled. Their clinical data were retrospectively analyzed, and their follow-ups were continued until March 31, 2022. Subsequently, univariate and multivariate Cox analyses, survival curves, and nomograms were adopted to explore the relationship between clinicopathological characteristics and recurrence or metastasis in patients with GIST.

RESULTS

Univariate and multivariate Cox analysis exhibited that the prognosis of patients was affected by tumor rupture ( = 0.040), tumor location ( < 0.001), tumor diameter ( = 0.016), mitotic figures ( < 0.001), and risk grade ( < 0.009). The above variables were selected to create the nomogram for 3-year disease-free survival (DFS). The 3-year the ROC (receiver operating characteristic) curves of the nomogram were (0.878 95% confidence interval [CI]: 0.871-0.939).

CONCLUSION

Collectively, risk factors affecting postoperative recurrence or metastasis of GIST consist of primary site of tumors, tumor rupture, tumor diameter >10 cm, high-risk tumor classification, and mitotic figures ≥10 per 50 HPFs. And the application of nomogram may help physicians provide individualized diagnosis and treatment for patients with GISTs following surgical resection.

摘要

目的

胃肠道间质瘤(GIST)是发生在消化道的潜在恶性肿瘤。本研究旨在探讨胃肠道间质瘤(GIST)复发和转移的危险因素及预后。

方法

回顾性分析 2018 年 1 月至 2019 年 12 月在温州医科大学附属第一医院接受手术的 422 例 GIST 患者的临床资料,对其进行随访,随访截止日期为 2022 年 3 月 31 日。采用单因素和多因素 Cox 分析、生存曲线和列线图探讨 GIST 患者临床病理特征与复发或转移的关系。

结果

单因素和多因素 Cox 分析显示,肿瘤破裂( = 0.040)、肿瘤部位( < 0.001)、肿瘤直径( = 0.016)、有丝分裂像( < 0.001)和危险度分级( < 0.009)影响患者预后。选择上述变量建立 3 年无病生存(DFS)的列线图。列线图的 3 年 ROC 曲线(0.878 95%CI:0.871-0.939)。

结论

影响 GIST 术后复发或转移的危险因素包括肿瘤原发部位、肿瘤破裂、肿瘤直径>10cm、高危肿瘤分级和每 50 高倍镜视野有丝分裂像≥10 个。列线图的应用可能有助于医生为接受手术切除的 GIST 患者提供个体化的诊断和治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27de/9313930/8e5b93bda7b5/CMMM2022-1127146.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27de/9313930/aa1f61b43aa4/CMMM2022-1127146.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27de/9313930/8e5b93bda7b5/CMMM2022-1127146.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27de/9313930/aa1f61b43aa4/CMMM2022-1127146.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27de/9313930/8e5b93bda7b5/CMMM2022-1127146.002.jpg

相似文献

1
Risk Factors and Prognostic Analysis of Gastrointestinal Stromal Tumor Recurrence-Metastasis.胃肠道间质瘤复发转移的危险因素及预后分析。
Comput Math Methods Med. 2022 Jul 18;2022:1127146. doi: 10.1155/2022/1127146. eCollection 2022.
2
Clinical characteristics and prognostic analysis of postoperative recurrence or metastasis of low-risk gastrointestinal stromal tumors.低危胃肠道间质瘤术后复发转移的临床特点及预后分析。
World J Surg Oncol. 2024 Feb 23;22(1):65. doi: 10.1186/s12957-024-03339-z.
3
Raf kinase inhibitor protein combined with phosphorylated extracellular signal-regulated kinase offers valuable prognosis in gastrointestinal stromal tumor.Raf 激酶抑制剂蛋白与磷酸化细胞外信号调节激酶联合提供胃肠道间质瘤有价值的预后信息。
World J Gastroenterol. 2023 Jul 14;29(26):4200-4213. doi: 10.3748/wjg.v29.i26.4200.
4
Novel Prognostic Nomogram for Recurrence-Free Survival of Patients With Primary Gastrointestinal Stromal Tumors After Surgical Resection: Combination of Prognostic Nutritional Index and Basic Variables.原发性胃肠道间质瘤患者手术切除后无复发生存的新型预后列线图:预后营养指数与基本变量的组合
Front Oncol. 2021 Jan 28;10:581855. doi: 10.3389/fonc.2020.581855. eCollection 2020.
5
[Clinicopathological features and prognosis of gastrointestinal stromal tumors with gene "homozygous mutation": a multicenter retrospective cohort study].基因“纯合突变”胃肠道间质瘤的临床病理特征及预后:一项多中心回顾性队列研究
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Sep 25;24(9):804-813. doi: 10.3760/cma.j.cn.441530-20210720-00293.
6
[A model to predict the recurrence of middle-high risk gastrointestinal stromal tumors based on preoperative fibrinogen and peripheral blood inflammatory indexes].基于术前纤维蛋白原和外周血炎症指标预测中高危胃肠道间质瘤复发的模型
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Sep 25;23(9):896-903. doi: 10.3760/cma.j.cn.441530-20200613-00355.
7
Performance of risk stratification systems for gastrointestinal stromal tumors: A multicenter study.胃肠道间质瘤风险分层系统的性能:一项多中心研究。
World J Gastroenterol. 2019 Mar 14;25(10):1238-1247. doi: 10.3748/wjg.v25.i10.1238.
8
Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy.原发性胃肠道间质瘤(GIST)完全切除后风险分类的再评估:辅助治疗的指征。
Gastric Cancer. 2015 Apr;18(2):426-33. doi: 10.1007/s10120-014-0386-7. Epub 2014 May 23.
9
A new nomogram for recurrence-free survival prediction of gastrointestinal stromal tumors: Comparison with current risk classification methods.一种用于预测胃肠道间质瘤无复发生存的新诺莫图:与当前风险分类方法的比较。
Eur J Surg Oncol. 2019 Jun;45(6):1109-1114. doi: 10.1016/j.ejso.2018.12.014. Epub 2018 Dec 21.
10
Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.胃肠道间质瘤患者的预后分析:单一单位原发性疾病手术治疗经验。
Chin Med J (Engl). 2010 Jan 20;123(2):131-6.

引用本文的文献

1
Development and validation of a prognostic nomogram for gastric GIST patients under 65 years of age.65岁以下胃间质瘤患者预后列线图的开发与验证
Discov Oncol. 2025 Jul 11;16(1):1313. doi: 10.1007/s12672-025-03092-z.
2
Survival outcome and impact of delayed imatinib therapy in gastric gastrointestinal stromal tumors.伊马替尼延迟治疗对胃胃肠道间质瘤生存结局的影响
Front Surg. 2025 Apr 3;12:1569677. doi: 10.3389/fsurg.2025.1569677. eCollection 2025.
3
Retracted: Risk Factors and Prognostic Analysis of Gastrointestinal Stromal Tumor Recurrence-Metastasis.

本文引用的文献

1
A Retrospective Study of Postoperative Outcomes in 98 Patients Diagnosed with Gastrointestinal Stromal Tumor (GIST) of the Upper, Middle, and Lower Gastrointestinal Tract Between 2009 and 2019 at a Single Center in Poland.一项回顾性研究,纳入了 2009 年至 2019 年期间在波兰的一家单一中心接受手术治疗的 98 例上、中、下消化道胃肠道间质瘤(GIST)患者的术后结局。
Med Sci Monit. 2021 Oct 14;27:e932809. doi: 10.12659/MSM.932809.
2
Gastrointestinal stromal tumor: a review of current and emerging therapies.胃肠道间质瘤:当前和新兴疗法的综述。
Cancer Metastasis Rev. 2021 Jun;40(2):625-641. doi: 10.1007/s10555-021-09961-7. Epub 2021 Apr 19.
3
撤回:胃肠道间质瘤复发转移的危险因素及预后分析。
Comput Math Methods Med. 2023 Oct 18;2023:9803741. doi: 10.1155/2023/9803741. eCollection 2023.
4
Development and validation of a prognostic nomogram for gastrointestinal stromal tumors in the postimatinib era: A study based on the SEER database and a Chinese cohort.在伊马替尼时代后胃肠道间质瘤的预后列线图的开发和验证:基于 SEER 数据库和中国队列的研究。
Cancer Med. 2023 Aug;12(15):15970-15982. doi: 10.1002/cam4.6240. Epub 2023 Jun 17.
Gastrointestinal stromal tumours.
胃肠道间质瘤。
Nat Rev Dis Primers. 2021 Mar 18;7(1):22. doi: 10.1038/s41572-021-00254-5.
4
Recent advances in the management of gastrointestinal stromal tumor.胃肠道间质瘤治疗的最新进展
World J Clin Cases. 2020 Aug 6;8(15):3142-3155. doi: 10.12998/wjcc.v8.i15.3142.
5
Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment.胃肠道间质瘤:流行病学、诊断与治疗。
Curr Opin Gastroenterol. 2019 Nov;35(6):555-559. doi: 10.1097/MOG.0000000000000584.
6
Incidence of Gastrointestinal Stromal Tumors in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States.2001 - 2015年美国胃肠道间质瘤发病率:基于美国50个州的癌症统计分析
Cureus. 2019 Feb 22;11(2):e4120. doi: 10.7759/cureus.4120.
7
Gastrointestinal stromal tumor: clinicopathological characteristics and pathologic prognostic analysis.胃肠道间质瘤:临床病理特征与病理预后分析。
World J Surg Oncol. 2018 Dec 3;16(1):231. doi: 10.1186/s12957-018-1532-1.
8
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib.伊马替尼、舒尼替尼和瑞戈非尼治疗进展后晚期胃肠道间质瘤患者的伊马替尼再激发治疗
Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794623. doi: 10.1177/1758835918794623. eCollection 2018.
9
Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.胃肠道间质瘤增强子支持预测临床结局的转录因子网络。
Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5746-E5755. doi: 10.1073/pnas.1802079115. Epub 2018 Jun 4.
10
Gastrointestinal stromal tumors: A multidisciplinary challenge.胃肠道间质瘤:多学科的挑战。
World J Gastroenterol. 2018 May 14;24(18):1925-1941. doi: 10.3748/wjg.v24.i18.1925.